

Available online at www.sciencedirect.com



VIROLOGY

Virology 352 (2006) 380-389

www.elsevier.com/locate/yviro

# The G490E mutation in reverse transcriptase does not impact tRNA primer selection by HIV-1 with altered PBS and A-loop

Wenqin Xu, Casey D. Morrow \*

Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL 35294-0024, USA

Received 13 February 2006; returned to author for revision 29 March 2006; accepted 11 April 2006 Available online 15 June 2006

#### Abstract

The initiation of HIV-1 reverse transcription utilizes a cellular tRNA<sup>Lys,3</sup> as a primer. The 3' terminal 18-nucleotides of the cellular tRNA<sup>Lys,3</sup> are complementary to a region on the viral genome, designated as the primer binding site (PBS). Previous studies have shown that forcing HIV-1 to utilize alternative tRNA primers through alteration of the PBS results in viruses that revert to utilize tRNA<sup>Lys,3</sup> following in vitro replication. In some instances though, HIV-1 has been shown to select alternative tRNAs for initiation of reverse transcription if additional mutations upstream in the U5 region (A-loop) were made to be complementary to these alternative tRNAs. Recently, an HIV-1 has been described in which the U5 region distinct from the A-loop, designated as the primer activation site (PAS), was mutated in conjunction with the PBS to force the virus to use tRNA<sup>Lys1,2</sup> as a primer. An additional mutation in reverse transcriptase (RT), G490E, was found to facilitate the forced use of tRNA<sup>Lys1,2</sup> as the primer. In the current study, we have investigated the impact of the G490E mutation in RT on the selection and use of alternative primers by HIV-1. Viruses were first constructed in which the PBS and A-loop region were made complementary to tRNA<sup>Trp</sup>. Previous studies from our laboratory have shown that these viruses are unstable and mutate to select tRNA<sup>Met</sup> or tRNA<sup>Lys1,2</sup>. Analysis of the replication of viruses with the U5 and PBS complementary to tRNA<sup>Tp</sup> with or without the G490E mutation revealed no significant differences with respect to infectivity and viral growth in SupT1 or peripheral blood mononuclear cells (PBMC). In addition, the presence of the G490E mutation did not influence the capacity of this virus to revert to utilize tRNA<sup>Met</sup> as the primer for initiation of reverse transcription. In a previous study, we have described an HIV-1 that has been forced to utilize tRNA<sup>Lys1,2</sup> through mutations in the A-loop and PBS. The G490E RT mutation in this virus did not impact on the virus infectivity or growth in SupT1 or PBMC. We did not find a significant fitness advantage to viruses in which the A-loop and PBS were made complementary to tRNA<sup>Lys1,2</sup> that also contained the G490E mutation in RT. The results of these studies then establish that HIV-1 can be forced to use alternative primers through mutations in the U5 (PAS or A-loop) for certain tRNAs. Furthermore, for mutations in the A-loop and PBS, the RT does not play an important role in dictating the selection of the alternative primers to be used for initiation of reverse transcription. © 2006 Elsevier Inc. All rights reserved.

Keywords: tRNA; Reverse transcriptase; HIV-1; Primer binding site

#### Introduction

Reverse transcription of the retroviral RNA genome into a DNA intermediate is an essential step in virus replication. Initiation of reverse transcription occurs near the 5' end of the viral genome at a site designated as the primer binding site (PBS) (Panet and Berliner, 1978; Peters and Dahlberg, 1979;

Temin, 1981). The PBS is complementary to the 3' terminal 18nucleotides of the cellular tRNA that is used as the primer. The tRNA that is selected from the intracellular milieu for use as a reverse transcription primer is highly conserved amongst different retroviruses (Mak et al., 1997; Marquet et al., 1995). For example, human immunodeficiency virus (HIV-1) exclusively uses tRNA<sup>Lys,3</sup> for initiation of reverse transcription. The mechanism of how retroviruses select particular tRNAs probably involves multiple mechanisms. Previous studies with HIV-1 have found that the Gag and Gag-Pol proteins are assembled into virus-like particles which are enriched for tRNA<sup>Lys1,2</sup> and tRNA<sup>Lys,3</sup> (Kohorchid et al., 2000; Mak et al., 1994). Recent studies have shown that lysl tRNA synthetase is

<sup>\*</sup> Corresponding author. University of Alabama at Birmingham, Department of Cell Biology, 802 Kaul Building, 720 20th Street, South, Birmingham, AL 35294-0024, USA. Fax: +1 205 934 5733.

E-mail address: caseym@uab.edu (C.D. Morrow).

also enriched in virions, suggesting that this protein could chaperone tRNA<sup>Lys1,2,3</sup> into virions (Cen et al., 2002; Javanbakht et al., 2003; Jiang et al., 1994). Although tRNA<sup>Lys1,2,3</sup> are enriched in HIV virions, previous

studies have shown that HIV-1 has the capacity to select and use alternative (non-tRNA<sup>Lys,3</sup>) primers for replication (Das et al., 1995; Li et al., 1994; Wakefield et al., 1995). In early studies, it was found that alteration of the PBS to be complementary to a variety of primers resulted in the virus able to select and use these primers for a limited time of in vitro culture. Eventually, all of these viruses reverted back to utilize tRNA<sup>Lys,3</sup>. Followup studies found that additional mutations upstream of the PBS in a region designated as the A-loop allowed the virus to stably utilize some but not all alternative tRNAs that were examined (Kang and Morrow, 1999; Kang et al., 1997, 1999; Wakefield et al., 1996; Zhang et al., 1998). As a consequence of forcing HIV-1 to utilize these alternative tRNAs, the resultant viruses all exhibited a reduced growth as compared to the wild-type virus. Thus, even under conditions designed to promote the use of alternative tRNAs, including tRNA<sup>Lys1,2</sup> which is enriched in virions. HIV-1 has evolved towards a preference for the selection and use of tRNA<sup>Lys,3</sup> as the primer for high-level replication.

In a previous study, we reported on the construction and characterization of an HIV-1 which stably utilizes tRNA<sup>Lys1,2</sup> rather than tRNA<sup>Lys,3</sup> as the primer for reverse transcription (Kang and Morrow, 1999; Kang et al., 1999). This virus was initially derived from a culture of HIV-1 in which the PBS and A-loop region had been mutated to be complementary to tRNA<sup>Met</sup> (Kang et al., 1997). Viruses which use tRNA<sup>Met</sup> were identified from cultures in which the PBS and A-loop had been mutated to correspond to tRNA<sup>Trp</sup> (Kang et al., 1996). Thus, the parent virus for subsequent viruses that use tRNA<sup>Lys1,2</sup> or tRNA<sup>Met</sup> was derived from the in vitro culture of viruses in which the PBS and A-loop were mutated to be complementary to tRNA<sup>Trp</sup> (Kang and Morrow, 1999; Kang et al., 1996, 1997, 1999). The results from these studies highlight some of the complex evolution that can occur following modification of the PBS. In a recent study, a second HIV-1 virus that utilizes tRNA<sup>Lys1,2</sup> for initiation of reverse transcription was described (Abbink et al., 2004). For this study, the authors again made the PBS complementary to tRNA<sup>Lys1,2</sup> but mutated a region upstream of the A-loop designated as the primer activation signal (PAS) to be complementary to tRNA<sup>Lys1,2</sup>. The PAS is complementary to the T  $\phi$  C arm of tRNA<sup>Lys,3</sup>. The PAS does not contribute to tRNA-PBS annealing but is essential for initiation of tRNA primed reverse transcription. In vitro studies have demonstrated that HIV-1 primer usage can be switched from tRNA<sup>Lys,3</sup> to tRNA<sup>Lys1,2</sup> by the use of RNA templates containing the PAS and PBS double mutations (Beerens and Berkhout, 2002). Analysis of HIV-1 with PAS and PBS complementary to tRNA<sup>Lys1,2</sup> revealed that following extensive long-term in vitro culture HIV-1 could stably utilizes tRNA<sup>Lys1,2</sup> for replication. An additional mutation in the virus was found within the RT gene of HIV, a G490E mutation in the RT (RNase H) gene facilitated the virus replication and use of tRNA<sup>Lys1,2</sup> as the primer for replication.

In a current study, we wanted to determine whether the G490E mutation in RT would effect the selection of tRNA primers in HIV-1 in which the A-loop and PBS had been mutated to correspond to alternative tRNAs. Our first study utilized an HIV-1 in which the PBS and A-loop were mutated to be complementary to tRNA<sup>Trp</sup>, since our previous studies have suggested that this virus would naturally evolve to utilize tRNA<sup>Met</sup> and possibly tRNA<sup>Lys1,2</sup> following in vitro culture (Kang et al., 1996, 1997). We also determined the effect of the G490E mutation in RT on the replication of HIV-1 in which we have engineered to utilize tRNA<sup>Lys1,2</sup> through simultaneous mutations in the A-loop and PBS (Kang et al., 1999). The results of our studies demonstrate that for viruses which contain A-loop and PBS mutations, the G490E mutation in RT does not substantially impact on selection of primer tRNA and virus replication. The results are discussed with respect to the importance of the U5 region in the selection of the tRNA primer used for HIV-1 replication.

### Results

# *Effect of G490E mutation in RT on capacity of HIV-1 to select an alternative primer for replication*

In a previous study, we described construction and characterization of HIV-1 proviral genomes in which the PBS and A-loop region were mutated to be complementary to tRNA<sup>Trp</sup> (Kang et al., 1996). These proviral constructs used the HXB2 backbone, and the virus replication was analyzed in SupT1 cells. We found that viruses in which only the PBS was mutated to be complementary to the 3' terminal nucleotides of tRNA<sup>Trp</sup> reverted to utilize tRNA<sup>Lys,3</sup> following short-term in vitro replication in SupT1 cells. In contrast, viruses which contained both the A-loop and PBS complementary to tRNA<sup>Trp</sup> were unstable but reverted to utilize tRNA<sup>Met</sup> following in vitro culture. Subsequent characterization of the virus which uses tRNA<sup>Met</sup> revealed the potential to revert to use tRNA<sup>Lys1,2</sup> then back to tRNA<sup>Lys,3</sup> (Kang et al., 1997). In a recent study, we have further characterized the replication of the virus which utilizes tRNA<sup>Met</sup> (Moore-Rigdon et al., 2005). In this case, we found that viruses derived from NL-4 in which the PBS alone was altered to be complementary to tRNA<sup>Met</sup> were stable upon replication in either SupT1 or PBMC. Given the interesting and diverse phenotypes of the viruses which use tRNA<sup>Trp</sup>, we wanted to ascertain the effects of the G490E mutation in RT for effects that it would have on the growth of these viruses and potential to revert and utilize an alternative tRNA. Viruses were constructed using the NL-4 provirus in which the PBS and Aloop were mutated to be complementary to the 3' terminal nucleotides and anticodon region respectively of tRNA<sup>Trp</sup>. We also engineered the G490E mutation into the RT gene of these viruses and a wild-type control virus (Fig. 1A).

We first analyzed the infectivity of these viruses following transfection into 293 T cells. Virus supernatant was assayed for the capacity to infect the JC53BL indicator cell line and infectivity determined as previously described (Moore-Rigdon et al., 2005). The infectivity obtained from transfection of wild-

Α	U5-PBS	RT
NL-4 WT A	AGTCAGTGT <b>GGAAAATC</b> TCTAGCAG <b>TGGCGCCCGAACAGGGAC</b> TTGAAA	CGG <b>G</b> ATTA
NL-4-WT (G490E) A	AGTCAGTGT <b>GGAAAATC</b> TCTAGCAG <b>TGGCGCCCGAACAGGGAC</b> TTGAAA	CGG <b>A</b> ATTA
NL-4-Trp	AGTCAGTGT <b>GGAAAATC</b> TCTAGCAG <b>TGGTGACCCCGACGTGAT</b> TTGAAA	CGG <b>G</b> ATTA
NL-4-Trp (G490E)	AGTCAGTGT <b>GGAAAATC</b> TCTAGCAG <b>TGGTGACCCCGACGTGAT</b> TTGAAA	CGG <b>A</b> ATTA
NL4-Trp-AC	AGTCAGTGT <b>TCTGGAGT</b> TCTAGCAG <b>TGGTGACCCCGACGTGAT</b> TTGAAA	CGG <b>G</b> ATTA
NL4-Trp-AC (G490E)	AGTCAGTGT <b>TCTGGAGT</b> TCTAGCAG <b>TGGTGACCCCGACGTGAT</b> TTGAAA	CGGAATTA



Fig. 1. Characterization of HIV-1 with PBS complementary to tRNA<sup>Trp</sup>. (A) Sequences of HIV-1 and U5-PBS complementary to tRNA<sup>Trp</sup> and G490E mutation in RT. The proviral backbone NL-4 (NL-4-WT) was used for the construction genomes. The sequences in bold (GGAAAAT) correspond to the A-loop region that is complementary to the anticodon region of tRNA<sup>Lys,3</sup>. The 18-nucleotide (bold sequence) 3' to the A-loop region is the primer binding site (PBS), which is complementary to tRNA<sup>Lys,3</sup> for NL-4-WT (G490E). These viruses differ by a mutation in the RT gene (G to A nucleotide 4018 of the NL-4 sequence), which results in a G490E mutation. Proviral constructs in which the PBS and A-loop region/PBS were mutated to correspond to tRNA<sup>Trp</sup> were taken from a previous study (Kang et al., 1996). The region complementary to the anticodon region of tRNA<sup>Trp</sup> is denoted in bold (TCTGGAGT) and the PBS downstream of this region also noted in bold (NL-4-Trp; NL-4-Trp-AC). The G490E mutation was engineered into proviruses in which the PBS and PBS with A-loop were mutated to be complementary to tRNA<sup>Trp</sup> resulting in the notation G490E (NL-4-Trp (G490E); NL-4-Trp-AC (G490E)). (B) Infectivity of wild-type and mutant viruses from transfection of 293T cells. Proviral DNA was transfected into 293T cells, and the amount of infectious virus in the supernatant was determined using the JC53 assay (Derdeyn et al., 2000). The infectivity represents the amounts of infectious units divided by the levels of p24 antigen. The level of infectivity obtained from the wild-type virus (NL-4-WT) was set at 100%. The amounts of infectious virus obtained from the wild-type virus containing the G490E mutation in RT as well as the viruses with a PBS and PBS A-loop complementary to tRNA<sup>Trp</sup> containing the G490E mutation were also determined. The levels of p24 were determined by ELISA. Standard deviations are represented by the error bars.

type (NL-4) virus was set at 100% with the infectivities of the mutants compared to this level (Fig. 1B). The G490E mutation in the wild-type virus reduced the infectivity of the wild-type virus by approximately 60% in this assay. Viruses in which the PBS alone or PBS plus A-loop were mutated to be complementary to tRNA<sup>Trp</sup> demonstrated a reduced infectivity compared to the wild type. For the virus with only the PBS complementary to tRNA<sup>Trp</sup>, we observed an infectivity that was approximately 10% of that of the wild-type level, while for viruses with both PBS and A-loop, the infectivity was only 3% of the wild-type levels. Consistent with the results obtained with the wild-type virus, the G490E mutation in RT also reduced the infectivity of the viruses with a PBS complementary to tRNA<sup>Trp</sup>. In contrast, infectivities of virus with both the PBS

В

and A-loop complementary to tRNA<sup>Trp</sup> had similar infectivities (albeit very low), as the virus with the wild-type RT.

We next examined the infectivity of these viruses following continuous culture with SupT1 cells (Fig. 2A). We initiated the infections with equal amounts of infectious virus and followed the p24 levels in the cultured supernatant for approximately 35 days. The wild-type virus demonstrated a rise in p24 levels peaking at approximately day 14 post-initiation of culture. There were no clear-cut differences between the levels of p24 observed in cultures from the wild-type viruses with or without the G490E mutation in RT. In contrast, the viruses with the PBS only altered to be complementary to tRNA<sup>Trp</sup> demonstrated a delay in replication. By day 14 of culture, viruses with the wild-type RT began to increase, peaking at day 28 of culture.



Fig. 2. Replication of viruses in SupT1 cells. (A) Infections were initiated in SupT1 cells as described in the Materials and methods. Virus replication was monitored by the levels of p24 antigen in the culture supernatants selected at days following initiation of culture. The key is as follows: solid circles, NL-4-WT; open circles, NL-4-WT (G490E); open box, NL-4-Trp; closed box, NL-4-Trp (G490E); X, NL-4-Trp-AC; + NL-4-Trp-AC (G490E). Both proviruses containing the Trp-AC mutations did not have p24 antigen in the culture supernatants over the background value obtained from mock transfection. The data are representative of three independent virus infections. (B) The infectivity of virus obtained following day 35 of culture in SupT1 was determined using the JC53 assay. Infectivity represents the infectious units divided by the p24 antigen obtained from the cultured supernatant at day 35 post-infection as shown from panel A. Note that the viruses with the anticodon mutation complementary to Trp did not grow and therefore were not included in this assay. Virus obtained from NL-4-WT was set at 100%. The levels of NL-4-WT (G490E) and NL-4-Trp with and without the G490E are presented. Error bars are standard deviation.

viruses with the G490E mutation in RT were delayed but also began to increase approximately 7 days after (day 21 of culture), then increased to a level similar to that of the wild-type viruses by day 35. In contrast, viruses in which both the PBS and Aloop were mutated to be complementary to tRNA<sup>Trp</sup> did not grow in SupT1 under these culture conditions; regardless of whether the RT was mutated, both viruses did not show any increase in p24 following long-term in vitro culture.

One of the interesting features of the viruses in which the PBS is complementary to tRNA<sup>Trp</sup> is the propensity to revert to utilize tRNA<sup>Met</sup> or tRNA<sup>Lys,3</sup> (Kang and Morrow, 1999; Kang et al., 1996). In a previous study, we had identified viruses in

which both the PBS and A-loop complementary to tRNA<sup>Trp</sup> resulted in the virus to mutate to utilize tRNA<sup>Met</sup>. Since only the viruses with the PBS complementary to tRNA<sup>Trp</sup> grew in SupT1 cells, we analyzed the high molecular weight DNA from these viruses to determine if the PBS was stable. Analysis of the cultures derived from day 35 infection in SupT1 cells revealed that these viruses had reverted to utilize tRNA<sup>Met</sup>, regardless of whether or not the RT mutation was present (Table 1). Consistent then with our previous studies, we found that once the viruses had reverted to utilize tRNA<sup>Met</sup>, they grew to levels in our culture system consistent with that observed for the wildtype virus. Interestingly, we have analyzed the infectivity of viruses obtained after day 35 cultured in SupT1 cells (Fig. 2B). This time, we found that the wild-type virus with the G490E mutation was approximately 90% as infectious as the wild type which differs from the infectivity of this virus derived from transfection of 293 T cells. The reason for this difference is unclear but could be due to the source of the virus (293 T cells compared to SupT1 cells). Sequence analysis of the RT gene confirmed though that the viruses still had maintained the G490E mutation with no additional RT mutations (data not shown). In contrast, viruses in which the PBS was complementary to tRNA<sup>Trp</sup> (initially and following mutation to be complementary to tRNA<sup>Met</sup>) grew at approximately 10% the level of the wild-type virus. Thus, although the assays for p24 production show that the viruses are growing in a similar fashion as the wild-type virus at day 35, the infectivity is still relatively low compared to the wild-type virus as measured in the JC53 assay. Collectively, the results of these studies establish that the replication of the viruses in which the PBS was complementary to tRNA<sup>Trp</sup> was not influenced by the G490E mutation in HIV-1 RT. Furthermore, the propensity to revert to utilize an alternative tRNA (tRNA<sup>Met</sup>) or the further selection to generate a virus that uses tRNA<sup>Lys1,2</sup> was also not influenced by the RT mutation.

We next examined the infectivity of the viruses in PBMC. Again, the wild-type viruses with or without the G490E mutation in RT demonstrated substantial infectivity that peaked between days 7 and 14 post-initiation of the culture. There were no differences between the replication of the wild type containing the RT mutation. In contrast, viruses in which the PBS was altered to be complementary to tRNA<sup>Trp</sup> did not grow (or grew very poorly) following 35 days of in vitro culture, regardless of whether or not the viruses contained the mutation

Table	1	

DNA sequence of PBS	following	extended	cultures	in	SupT1	(Day	35	)
---------------------	-----------	----------	----------	----	-------	------	----	---

Input	U5-PBS	RT
NL-4-Trp <sup>a</sup>	PBS region is complementary to tRNA <sup>Met b</sup>	No change <sup>c</sup>
NL-4-Trp(G490E)	PBS region is complementary to tRNA <sup>Met</sup>	No change
NL-4-Trp-AC	No growth <sup>d</sup>	No growth
NL-4-Trp-AC(G490E)	No growth <sup>d</sup>	No growth

<sup>a</sup> Input proviral DNA.

<sup>b</sup> The PBS from integrated proviruses complementary to tRNA<sup>Met</sup>.

<sup>c</sup> No change in WT or G490E mutation of RT from input.

<sup>d</sup> This virus did not grow; no PCR product recovered.

in RT (data not shown). The p24 values from these viruses did not increase over the culture period; similar to what we found with the viruses which contained both the A-loop and PBS complementary to tRNA<sup>Trp</sup>, these viruses also did not grow during this culture period.

The results of these studies suggest then that the mutation in RT did not effect the replication of the wild-type virus in either SupT1 cells or PBMC. Furthermore, the replication of viruses in which the PBS was complementary to tRNA<sup>Trp</sup> alone was slightly delayed in SupT1 cells as a result of the 490E mutation. However, regardless of RT mutation, viruses contained both the anticodon and PBS complementary to tRNA<sup>Trp</sup> were non-infectious as determined by the infectivity assay from transfected cell culture supernatants as from analysis of growth in SupT1 and PBMC cultures.

# Effect of G490E mutation in RT on virus replication that uses $tRNA^{Lys1,2}$ for reverse transcription

In a previous study, we have identified and characterized an HIV-1 in which it utilized tRNA<sup>Lys1,2</sup> rather than tRNA<sup>Lys,3</sup> for replication (Kang and Morrow, 1999; Kang et al., 1999).

В

Interestingly, this virus was identified from the characterization of the long-term replication of the virus that uses tRNA<sup>Met</sup> for replication. We found that viruses could be stabilized to utilize tRNA<sup>Lys1,2</sup> if additional mutations were made within the A-loop region to be complementary to the anticodon of tRNA<sup>Lys1,2</sup>. A recent study also characterized an HIV-1 which utilizes tRNA<sup>Lys1,2</sup> for replication (Abbink et al., 2004). In this case, additional mutations, made upstream of the A-loop region at a position identified as the primer activation signal, were required to be complementary to tRNA<sup>Lys1,2</sup> in order for the virus to stably utilize this tRNA for replication. During the characterization of this virus, the G490E mutation in RT was identified and postulated to co-operatively help the virus to maintain the use of tRNA<sup>Lys1,2</sup>. Since the G490E mutation in RT did not impact on the stability or selection of tRNAs with viruses in which the PBS was altered to be complementary to tRNA<sup>Trp</sup>, we wanted to determine whether or not this would be specific for the virus that uses tRNA<sup>Lys1,2</sup> as a result of A-loop modifications. In these studies, we made use of our previously described mutant in which both the A-loop and PBS were mutated to be complementary to tRNA<sup>Lys1,2</sup> (Fig. 3A). This region was cloned into the NL-4 provirus and the infectivity as well as replication

A U5-PBS			
NL-4 WT	AGTCAGTGT <b>GGAAAATC</b> TCTAGCAG <b>TGGCGCCCGAACAGGGAC</b> TTGAAA	CGG <b>G</b> ATTA	
NL-4-WT (G490E)	AGTCAGTGT <b>GGAAAATC</b> TCTAGCAG <b>TGGCGCCCGAACAGGGAC</b> TTGAAA	CGG <b>A</b> ATTA	
NL-4-Lys1,2-AC	AGTCAGTGT <b>GAAGAGTC</b> TCTAGCAG <b>TGGCGCCCAACGTGGGGC</b> TTGAAA	CGG <b>G</b> ATTA	
	AGTCAGTGTCAACAGTCTCTAGCAGTCCCCCAACCTCCCCCTCCAAA	CGGAATTA	



Fig. 3. Characterization of HIV-1 with PBS and A-loop complementary to tRNA<sup>Lys1,2</sup>. (A) Sequence of HIV-1 with U5-PBS complementary to tRNA<sup>Lys1,2</sup>. Proviral constructs in which the A-loop and PBS complementary to tRNA<sup>Lys,3</sup> (NL-4-WT) with and without mutations in the RT (G490E) are depicted as in Fig. 1A. A proviral construct NL-4-Lys12-AC in which the A-loop and PBS are complementary to tRNA<sup>Lys1,2</sup> (shown in bold) was taken from a previous study (Moore-Rigdon et al., 2005). Mutations in the RT gene (G490E) were constructed into the proviral clone to give NL-4-Lys12-AC (G490E). (B) Infectivity of wild type and HIV with PBS and A-loop complementary to tRNA<sup>Lys1,2</sup>. The infectivities of wild type and NL-4-Lys12-AC and NL-4-Lys12-AC (G490E) were determined following transfection of proviral constructs into the 293T cells. The amount of infectious units obtained in the supernatants was determined by the JC53 assay; the levels of p24 antigens were measured by ELISA. Infectivity for the wild type (IUs/p24) was set at 100%. The values for the wild type with the G490E mutation (NL-4-WT (G490E)) and viruses in which the PBS and A-loop were mutated to be complementary to tRNA<sup>Lys1,2</sup> (NL-4-Lys12-AC) with and without the G490E mutation were determined. The value for wild type was set at 100%. The bars indicate standard deviation.

in SupT1 and PBMC was determined. We first analyzed the infectivity of viruses obtained following transfection in 293 T cells. As presented previously, we found that wild-type viruses, which contained the G490E mutation in RT, had approximately 40% the infectivity of wild-type viruses. Virus which contained the A-loop and PBS mutated to be complementary to the tRNA<sup>Lys1,2</sup> had infectivities that were approximately 10% of that of the wild-type virus (regardless of whether or not the RT mutation was present) (Fig. 3B).

We first analyzed the replication of these viruses in SupT1 cells (Fig. 4A). Cultures were initiated with similar amounts of infectious units, and the amounts of p24 produced in the culture supernatant were analyzed over a 35-day culture period. As shown previously for the wild type, the presence or absence of the G490E mutation in RT did not significantly impact on the replication of the virus in SupT1 cells. We found a rise in p24



Fig. 4. Replication of HIV-1 with U5-PBS complementary to tRNA<sup>Lys1,2</sup> containing the G490E mutation. (A) SupT1 cells were infected with NL-4 wild type (with and without G490E mutation) and NL-4-Lys12-AC (with and without G490E mutation). Infection was monitored by assaying levels of p24 antigen in the culture supernatants at selected days for 35 days. (B) PBMC. Infection of the NL-4-WT (with and without G490E mutation) and NL-4-Lys12-AC (with and without G490E mutation) was established in PBMC. Infection was monitored by levels of p24 antigen in the culture supernatant at selected days for 35 days. Key to both panels: closed circles, NL-4-WT; open circles, NL-4-WT (G490E); closed square, NL-4-Lys12-AC; open square, NL-4-Lys12-AC (G490E). The data presented are representative from three independent infections.

production starting at day 7 that peaked by 14 days postinitiation of culture and was maintained for the 35-day culture period. Interestingly, similar results were found with viruses in which the PBS and A-loop were altered to be complementary to tRNA<sup>Lys1,2</sup>. In this case, we noted a slight delay in the production of p24 in the culture supernatant at day 7 compared to the wild-type levels, but by day 14, these levels had reached a peak value that was similar to that for the wild-type virus. There was no difference with respect to the amounts of p24 produced in the cultures where viruses contained the 490E mutation in RT. We next characterized the replication of these viruses in PBMC (Fig. 4B). Again, for these studies, we initiated the cultures with similar amounts of IUs and followed the replication by the presence of p24 in the culture supernatant. There was no significant difference between the replication of the wild-type virus with or without the G490E mutation. In contrast, viruses in which the PBS and anticodon were complementary to tRNA<sup>Lys1,2</sup> grew poorly in PBMC, reaching levels approximately 1% of that of the wild-type virus by day 14 and day 21 post-initiation of culture. The levels of p24 were significantly higher than that of the background levels (or levels obtained from viruses which contained the PBS complementary to tRNA<sup>Trp</sup>) indicating that replication had occurred. We next analyzed the U5-PBS from viruses which were complementary to tRNA<sup>Lys1,2</sup>. Consistent with our previous studies, we found that these viruses maintained a PBS complementary to tRNA<sup>Lys1,2</sup> (data not shown). There is no difference between viruses which contained the G490E mutation and the wild-type RT. Furthermore, sequence analysis of the RT gene revealed that the mutation was stable following in vitro culture in PBMC.

Given that the viruses were stable following culture in PBMC, we wanted to determine if there was a subtle effect of the G490E mutation that would allow a greater fitness in culture. For these studies, we initiated cultures with varying input ratios of wild type to G490E mutated viruses (Table 2). As a control, we first analyzed the wild-type virus replication using input ratios of 10:1 (wild type) RT to G490E mutation, 1:1 and 1:10, respectively. In cases where the dominant virus that initiated cultures was either the wild-type RT or the mutant RT, we found that these viruses still dominated following 35 days of culture in PBMC. Thus, at a 10:1 ratio of either virus, there was no significant advantage of the wild type over the mutant RT. Initiating cultures with equal amounts of infectious units followed by analysis of the RT revealed a similar equal distribution following TA cloning of PCR amplified RT genes from these cultures at day 35. In this case, 10 of the 18 TA clones obtained were from the wild-type RT as the remaining 8 were from the G490E mutant. We next compared the fitness of viruses in which both the A-loop and PBS were complementary to tRNA<sup>Lys1,2</sup>. Using the same strategy for analysis, we found that again if the dominant virus contained either the wild-type or mutant RT, we recovered mainly this RT following in vitro culture of 35 days with the PBMC. Initiating cultures with equal amounts of virus followed by TA cloning of the amplified RT genes after 35 days of culture in PBMC revealed a slight advantage for the RT G490E mutant compared to the wild type (13 of 19 TA clones, compared to 6 of 19 TA clones). This result

Table 2 Replication competition experiments between HIV with WT or G490E mutation in RT

Virus <sup>a</sup>	Input <sup>b</sup> RT-WT:RT-G3600A	Sample <sup>c</sup>	Sequencing of RT Region
NL-4	10 to 1	PCR	RT-WT
NL-4	1 to 1	TA cloning	10/18 RT-WT, 8/18 RT-G490E
NL-4	1 to 10	PCR	RT-G490E
NL-4-Lys1,2-AC	10 to 1	PCR	RT-WT
NL-4-Lys1,2-AC	1 to 1	TA cloning	6/19 RT-WT, 13/19 RT-G490E
NL-4-Lys1,2-AC	1 to 10	PCR	RT-G490E

<sup>a</sup> Virus used in competition (NL-4-WT or NL-4-Lys1,2-AC).

<sup>b</sup> Starting ratio of virus in infectious units as determined by JC53-BL assay. <sup>c</sup> Sample used for DNA sequencing. PCR refers to direct sequencing of PCR product for high molecular weight DNA. No ambiguities in the RT region encompassing G490E. TA cloning refers to PCR product cloned into TA vector and individual colonies sequenced.

suggests there could be a fitness advantage for viruses which contain the G490E mutation in RT that utilized tRNA<sup>Lys1,2</sup> for initiation of reverse transcription. However, the dominant effect for viruses to utilize tRNA<sup>Lys1,2</sup> or other alternative tRNAs appears to reside in the PBS and U5 region rather than the RT mutation.

#### Discussion

In the current study, we have investigated the potential of a mutation in the HIV-1 RT (G490E) to influence primer selection. This mutation in RT was previously identified to facilitate the use of tRNA<sup>Lys1,2</sup> as a primer for HIV-1 reverse transcription (Abbink et al., 2004). We found that viruses in which the PBS alone or PBS and A-loop were mutated to be complementary to tRNA<sup>Trp</sup> were not influenced by the presence or absence of the G490E mutation in RT. Regardless of whether the RT mutation was present, the virus with a PBS complementary to tRNA<sup>Trp</sup> mutated to use tRNA<sup>Met</sup>. We next examined the effects of the G490E mutation on the replication of HIV-1 in which the A-loop and PBS had been altered to be complementary to tRNA<sup>Lys1,2</sup>. Previous studies from our laboratory had demonstrated that this virus stably maintains a PBS complementary to tRNA<sup>Lys1,2</sup> (Kang and Morrow, 1999, Kang et al., 1999). Comparison of the replication of viruses with and without the G490E mutation revealed no substantial differences. Thus, while the G490E mutation in RT might facilitate the replication of HIV-1 with a PBS and upstream region in the U5 (PAS) complementary to tRNA<sup>Lys1,2</sup>, this RT mutation does not affect the replication of viruses with mutations in the A-loop region of U5 that facilitate the use of alternative tRNA primers.

Previous studies from our laboratory and others have used genetic manipulation of the HIV-1 genome to gain insights into the mechanism by which HIV-1 selects the primer tRNA required for HIV-1 replication. We and others have shown that alteration of the PBS so as to be complementary to alternative tRNAs results in viruses that utilize these tRNAs for shortterm in vitro replication but rapidly revert back to utilize

tRNA<sup>Lys,3</sup> (Das et al., 1995; Jiang et al., 1994; Wakefield et al., 1995). To stabilize the use of these alternative tRNAs, we have made additional changes within the U5 region that are complementary to the anticodon region of certain tRNAs. This strategy has allowed us to derive HIV-1 which can stably utilize tRNA<sup>Met</sup>, tRNA<sup>Lys1,2</sup>, tRNA<sup>His</sup> and more recently tRNA<sup>Glu</sup> (Dupuy et al., 2003; Kang and Morrow, 1999, Kang et al., 1997, 1999; Wakefield et al., 1996; Zhang et al., 1998). Not all U5-PBS combinations allow the virus to utilize alternative tRNAs such that viruses with A-Loop-PBS combinations complementary to tRNA<sup>Ile</sup>, tRNA<sup>Pro,</sup>, and tRNA<sup>Trp</sup> were not stable and reverted back to utilize tRNA<sup>Lys,3</sup> or in some instances (tRNA<sup>Trp</sup>), alternative tRNAs. In a previous study, we characterized the virus that utilizes tRNA<sup>His</sup> for replication. From DNA sequence analysis of integrated proviruses, we found that there were no consistent mutations in the structural genes (nucleocapsid and RT), suggesting that mutations did not occur to compensate for the use of alternative tRNAs (Zhang et al., 1996, 1998). In support of this, we noted that the virus could rapidly utilize tRNA<sup>His</sup> following mutation of the A-loop and PBS, suggesting that no additional mutations in structural genes were required. It is important to note though that these viruses, as well as all of our viruses which utilize alternative tRNAs for replication, do not replicate with the same efficiency as the wild-type HIV-1. Similar to what we have presented in this study, we noted that for the most part, viruses in which the PBS or PBS and A-loop had been altered, exhibit approximately 1/10 the infectivity as that for the wild-type HIV-1. Thus, the recent study by Abbink et al. was of particular interest because the authors have shown that HIV-1 can be forced to utilize tRNA<sup>Lys1,2</sup> following mutations within the PBS and U5 (PAS, not A-loop region) (Abbink et al., 2004). Characterization of this virus revealed an additional mutation in the RT gene, G490E, which facilitated the replication of HIV-1 with a PBS complementary to tRNA<sup>Lys1,2</sup>. The basis of our experiments then was to test whether or not this mutation in HIV-1 RT could impact on viruses which utilized other tRNAs (tRNA<sup>Trp</sup>) as well as a virus in which we had described that utilizes tRNA<sup>Lys1,2</sup> but contains a mutation within the A-loop rather than the PAS. The results of our studies clearly show that the G490E mutation does not substantially effect the replication or the primer utilization of the viruses in our study that have been engineered to be complementary to tRNA<sup>Trp</sup> or tRNA<sup>Lys1,2</sup>. Interestingly, the virus which was engineered to be complementary to tRNA<sup>Trp</sup> has, in previous studies, been shown to mutate in culture to utilize tRNA<sup>Met</sup> or tRNA<sup>Lys1,2</sup> under the appropriate conditions (Kang et al., 1996). If the HIV-1 RT G490E mutation facilitated the use of tRNA<sup>Lys1,2</sup>, we would have expected the virus to utilize tRNA<sup>Trp</sup> to mutate directly to utilize tRNA<sup>Lys1,2</sup> or during the culture period revert to selectively utilize tRNA<sup>Lys1,2</sup>. Clearly, this was not observed in our studies. Thus, we believe that the G490E mutation in RT, while it can contribute some to the increased HIV-1 replication for the virus with the PBS complementary to tRNA<sup>Lys1,2</sup>, could only be manifested in the viral competition experiments between isogenic genomes that only contain the G490E

mutation (Table 2). We did not see any changes in the preference of viruses that were engineered to utilize  $tRNA^{Trp}$  to select  $tRNA^{Lys1,2}$ .

The results of our studies and Abbink et al. support the concept that the U5-PBS region is the major determinant for the selection of the tRNA primer, and that HIV-1 can be forced to utilize alternative primers through mutations in the U5 and PBS. Alteration of the PBS with either the A-loop or PAS can result in HIV-1 stably utilizing tRNA<sup>Lys1,2</sup> for replication. However, in each case, the virus does not grow as well as the wild-type virus. This result is interesting when in the context that tRNA<sup>Lys1,2</sup> is incorporated into the HIV-1 genome at levels similar to and many times greater than that for the preferred tRNA primer. tRNA<sup>Lys,3</sup> (Jiang et al., 1993). If primer selection relied merely on just the position of the tRNA primer in close proximity to the PBS, one would suspect that alteration of the PBS and A-loop/ PAS to be complementary to tRNA<sup>Lys1,2</sup> should result in a virus that has replication characteristics similar to that of the wildtype virus. Indeed, slight mutations in RT to accommodate the differences between tRNA<sup>Lys,3</sup> and tRNA<sup>Lys1,2</sup> (such as the G490E mutation) would be expected to occur when the virus was forced to utilize tRNA<sup>Lys1,2</sup> that would lead to viruses with replication characteristics similar to that of the wild-type virus. The fact that all viruses in which the PBS has been altered to be complementary to alternative tRNAs have replication characteristics that differ from the wild-type virus suggests that primer selection might be coupled with other elements of the viral replication cycle. Previous studies from this laboratory have suggested that primer selection is coupled with translation in that tRNAs which are aminoacylated are most effectively selected as primers for HIV-1 reverse transcription (Kelly and Morrow, 2003; Kelly et al., 2003). These results lead to the suggestion that HIV-1 primer selection could possibly occur in conjunction with HIV-1 translation and/or the switch from translation to encapsidation of the viral genomic RNA. With respect to this issue, it is possible that the mutations required in the U5 region (PAS and/or A-loop) act in a similar fashion to reduce the replication of HIV-1 to facilitate the selection of alternative tRNAs. Consequently, this implies that HIV-1 selects the tRNA primer from a pool of intracellular tRNAs that is highly enriched with tRNA<sup>Lys,3</sup> to facilitate high-level replication. Alteration of the U5-PBS region results in a virus that replicates slower, possibly because the virus required tRNAs that are not dominant in the intracellular pool (e.g., tRNA<sup>Lys1,2</sup>). Additional experiments with mutations in the U5 region (PAS and A-loop) would be required to substantiate this possibility and further define the mechanism of primer selection.

### Materials and methods

### Tissue culture

The SupT1 cells were maintained in RPMI 1640, supplemented with 15% fetal bovine serum (FBS) and 1% antibiotic– antimycotic. The 293 T cells were maintained in DMEM plus 10% FBS and 1% antibiotic–antimycotic. Human peripheral blood mononuclear cells (PBMC) were collected, stimulated using rIL-2 and phytohemagglutinin (PHA) (Sigma, St. Louis, MO), and maintained as described previously (Dupuy et al., 2003). All the cell culture media were from Cellgro by Mediatech, Herndon, VA.

# Construction of NL4-3 proviruses containing PBS and RT mutations

The NL-4-Lys1,2-AC mutant was described as previously (Moore-Rigdon et al., 2005). For the construction of NL-4-Trp and NL-4-Trp-AC mutants, proviral clones pHXB2-Trp and Trp-AC (Kang et al., 1996) were used to provide the U5-PBS region. After digestion with *HpaI* and *Bss*HII restriction enzymes, an 868-bp fragment that contained the 5' LTR, PBS, and leader region gag of HXB2 was separated and cloned into the NL4-3 HIV-1 proviral plasmid using *HpaI* and *Bss*HII restriction sites. All resulting NL4-3 constructs were verified by DNA sequencing.

To construct the RT mutation, the RT region of NL-4 PBS mutants was cloned into Litmus28 vector after digestion by AgeI and EcoRI. QuickChange site-directed mutagenesis of RT region was carried out on Litmus28 using PCR methods; template DNA (400 ng), pfu Turbo DNA polymerase (Stratagene), Turbo DNA polymerase buffer, and dNTPs were used for PCR as described by the manufacturer, PCR was performed by three cycling (95 °C for 30 s, 55 °C for 1 min, and 68 °C for 5 min) for 16 cycles, then elongation for 10 min at 68 °C. The synthetic oligonucleotides primers for mutant RT were 5'-TCTAGCTTTGCAGGATTCGGAATTAGAAG-TAAACATAGTGAC-3' (sense) and 5'-GTCACTATGTT-TACTTCTAATTCCGAATCCTGCAAAGCTAGA-3' (antisense). The underlined nucleotides are the ones changed from the wild type. After PCR the methylated parental DNA template was digested with DpnI for 1 h at 37 °C, and then the reaction mixture containing DNA was transformed into DH5- $\alpha$  cells. Colonies were selected on LB agar plates with ampicillin (100 µg/ml). The mutations were confirmed by DNA sequencing. Finally, the segment of RT region was separated from Litmus28 after digestion by AgeI and EcoRI and ligated to NL-4 that had been digested by AgeI and EcoRI.

### DNA transfections

Transfections were performed according to the protocol for the Fugene 6 Transfection Reagent (Roche Molecular Biochemicals, Indianapolis, IN). Briefly, 2  $\mu$ g of proviral plasmid DNA and 6  $\mu$ l Fugene reagent were added to 200  $\mu$ l of DMEM (no FBS). This mixture was incubated at room temperature for approximately 30 min then added drop-wise to one well of a 6-well plate containing 50% confluent 293 T cells in DMEM with 10% FBS. The transfections were incubated overnight at 37 °C, then the medium was replaced with fresh DMEM containing 10% FBS. After 48 h, all supernatants were collected and filtered through 0.45- $\mu$ mpore-size syringe filters and stored at -80 °C. Supernatants from transfected cells were assayed for HIV-1 p24 antigen by ELISA (Beckman Coulter, Miami, FL). Infectivity was also determined by JC53BL assay as described previously (Moore-Rigdon et al., 2005).

### Infection of SupT1 and PBMC

Infections were performed by inoculating  $1 \times 10^6$  SupT1 cells or  $5 \times 10^6$  PHA-stimulated PBMC with viral supernatant containing 1000 IU of virus. Following incubation for 2 h at 37 °C, with shaking every 30 min, virus/PBMC mixtures were transferred to 25-cm<sup>2</sup> tissue culture flasks, and the final volumes were adjusted to 10 ml with RPMI 1640, containing 15% FBS. PBMC were also cultured with 30 U/ml rIL-2.

Every 3 days, the infected SupT1 cells were passaged 1:5. For PBMC cultures, half of medium was replaced every 3 days without removing PBMC. Every 7 days, 1 ml of cell suspension was removed for SupT1 and PBMC cultures and centrifuged at 24,000 × g for 2 min. Supernatant was separated from the cell pellets and stored at -80 °C for further analysis by p24 ELISA and JC53BL infectivity assays. Cell pellets were also stored at -80 °C for isolation of high molecular weight DNA. Once the SupT1 cell culture was cleared of cells,  $1 \times 10^6$  SupT1 cells were added to the culture every 3 days. Every 14 days, an additional  $5 \times 10^6$  PHA-stimulated PBMC were added to PBMC culture.

## Dual infection assay

Virus with wild-type RT or mutant RT was mixed with the ratio of wild-type RT to mutant RT as follows: A: 10 IU to 1000 IU; B: 1000 IU to 1000 IU; and C: 1000 IU to 10 IU. SupT1 and PBMC cells were infected by different mixtures as described in the previous section. At day 35, the cell pellets were collected for PCR and DNA sequence analysis.

### Subcloning of PCR products and DNA sequencing

High molecular weight DNA was extracted from infected SupT1 or PBMC cell pellets following the instructions of Wizard Genomic DNA Isolation Kit (Promega). The regions of U5-PBS and RT were amplified by PCR from the high molecular weight DNA. The primers used to amplify U5-PBS regions are 5'-CGGAATTCTCTCTCTAGCCTCCGCTAGTC-3' and 5'-CCTTGAGCATGCGATCTACCACACAAGGC-3'. The primers used to amplify RT regions are 5'-GACAGAG-TATTGGCAAGCCACCTGGAT-3' and 5'-GCCA-TATTCGTGGGCTACAGTCTACTACTA'. The resulting PCR products were gel purified and ligated to the pGEM-T Easy vector (Promega), and the ligation mixes were used to transform competent *Escherichia coli* DH5- $\alpha$  cells. Individual colonies were screened for DNA inserts, and the DNA sequence was determined by automated sequencing.

#### Acknowledgments

We thank the members of the Morrow Laboratory for their helpful suggestions. We thank Adrienne Ellis for the preparation of the manuscript. The DNA sequencing was carried out by the UAB CFAR DNA Sequencing Core (AI 27767). C.D.M. acknowledges helpful suggestions from MAR. This research was supported by a grant from the NIH (AI34749).

#### References

- Abbink, T.E.M., Beerens, N., Berkhout, B., 2004. Forced selection of a human immunodeficiency virus type 1 that uses a non-self tRNA primer for reverse transcription: involvement of viral RNA sequences and the reverse transcriptase enzyme. J. Virol. 78 (19), 10706–10714.
- Beerens, N., Berkhout, B., 2002. Switching the in vitro tRNA usage of HIV-1 by simultaneous adaptation of the PBS and PAS. RNA 8, 357–369.
- Cen, S., Javanbakht, H., Kim, S., Shiba, K., Craven, R.C., Rein, A., Ewalt, K.L., Schimmel, P., Musier-Forsyth, K., Kleiman, L., 2002. Retrovirusspecific packaging of aminoacyl-tRNA synthetases with cognate primer tRNAs. J. Virol. 76, 13111–13115.
- Das, A.T., Klaver, B., Berkhout, B., 1995. Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA<sup>Lys,3</sup>. J. Virol. 69 (5), 3090–3097.
- Derdeyn, C.A., Decker, J.M., Sfakianos, J.N., Wu, X., O'Brien, W.A., Ratner, L., Kappes, J.C., Shaw, G.M., Hunter, E., 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74, 8358–8367.
- Dupuy, L.C., Kelly, N.J., Elgavish, T.E., Harvey, S.C., Morrow, C.D., 2003. Probing the importance of tRNA Anticodon: human immunodeficiency virus type 1 (HIV-1) RNA genome complementarity with an HIV-1 that selects tRNA<sup>Glu</sup> for replication. J. Virol. 77 (16), 8756–8764.
- Javanbakht, H., Halwani, R., Cen, S., Saadatmand, J., Musier-Forsyth, K., Gottlinger, H., Kleiman, L., 2003. The interaction between HIV-1 *Gag* and human lysyl-tRNA synthetase during viral assembly. J. Biol. Chem. 278 (30), 27644–27651.
- Jiang, M., Mak, J., Ladha, A., Cohen, E., Klein, M., Rovinski, B., Kleiman, L., 1993. Identification of tRNAs incorporated into wild-type and mutant human immunodeficiency virus type 1. J. Virol. 67, 3246–3253.
- Jiang, M., Mak, J., Huang, Y., Kleiman, L., 1994. Reverse transcriptase is an important factor for the primer tRNA selection in HIV-1. Leukemia 8 (Suppl. 1), S149–S151.
- Kang, S.-M., Morrow, C.D., 1999. Genetic analysis of a unique human immunodeficiency virus type 1 (HIV-1) with a primer binding site complementary to tRNAMet supports a role for U5-PBS stem-loop RNA structures in initiation of HIV-1 reverse transcription. J. Virol. 73, 1818–1827.
- Kang, S.M., Wakefield, J.K., Morrow, C.D., 1996. Mutations in both the U5 region and the primer-binding site influence the selection of the tRNA used for the initiation of HIV-1 reverse transcription. Virology 222, 401–414.
- Kang, S.-M., Zhang, Z., Morrow, C.D., 1997. Identification of a sequence within U5 required for human immunodeficiency virus type 1 to stably maintain a primer binding site complementary to tRNAMet. J. Virol. 71 (1), 207–217.
- Kang, S.-M., Zhang, Z., Morrow, C.D., 1999. Identification of a human immunodeficiency virus type 1 that stably uses tRNA<sup>Lys1,2</sup> rather than tRNA<sup>Lys,3</sup> for initiation of reverse transcription. Virology 257, 95–105.
- Kelly, N.J., Morrow, C.D., 2003. Yeast tRNA<sup>Phe</sup> expressed in human cells can be selected by HIV-1 for use as a reverse transcription primer. Virology 313, 354–363.
- Kelly, N.J., Palmer, M.T., Morrow, C.D., 2003. Selection of retroviral reverse transcription primer is coordinated with tRNA biogenesis. J. Virol. 77, 8695–8701.
- Kohorchid, A., Javannbakht, H., Wise, S., Halwani, R., Parniak, M.A., Wainberg, M.A., Kleiman, L., 2000. Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA<sup>Lys,3</sup> into HIV-1. J. Mol. Biol. 299, 17–26.
- Li, X., Mak, J., Arts, E.J., Gu, Z., Kleiman, L., Wainberg, M.A., Parniak, M.A., 1994. Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication. J. Virol. 68 (10), 6198–6206.
- Mak, J., Jiang, M., Wainberg, M.A., Hammarskjold, M.-L., Rekosh, D., Kleiman, L., 1994. Role of Pr160<sup>gag-pol</sup> in mediating the selective

incorporation of  $tRNA^{Lys}$  into human immunodeficiency virus type 1 particles. J. Virol. 68, 2065–2072.

- Mak, J., Khorchid, A., Cao, Q., Huang, Y., Lowy, I., Parniak, M.A., Prasad, V.R., Wainberg, M.A., Kleiman, L., 1997. Effects of mutations in Pr160<sup>gag</sup>-pol upon tRNA<sup>Lys,3</sup> and Pr160<sup>gag-pol</sup> incorporation into HIV-1. J. Mol. Biol. 265, 419–431.
- Marquet, R., Isel, C., Ehresmann, C., Ehresmann, B., 1995. tRNAs as primer of reverse transcriptases. Biochimie 77, 113–124.
- Moore-Rigdon, K.L., Kosloff, B.R., Kirkman, R.L., Morrow, C.D., 2005. Preferences for the selection of unique tRNA primers revealed from analysis of HIV-1 replication in peripheral blood mononuclear cells. Retrovirology 2 (21).
- Panet, A., Berliner, H., 1978. Binding of tRNA to reverse transcriptase of RNA tumor viruses. J. Virol. 26, 214–220.
- Peters, G., Dahlberg, J.E., 1979. RNA-directed DNA synthesis in Moloney murine leukemia virus: Interaction between the primer tRNA and the genome RNA. J. Virol. 31, 398–407.

- Temin, H.M., 1981. Structure, variation and synthesis of retrovirus long terminal repeat. Cell 27, 1–3.
- Wakefield, J.K., Wolf, A.G., Morrow, C.D., 1995. Human immunodeficiency virus type 1 can use different tRNAs as primers for reverse transcription but selectively maintains a primer binding site complementary to tRNA<sup>Lys,3</sup>. J. Virol. 69, 6021–6029.
- Wakefield, J.K., Kang, S.-M., Morrow, C.D., 1996. Construction of a type 1 human immunodeficiency virus that maintains a primer binding site complementary to tRNA<sup>His</sup>. J. Virol. 70, 966–975.
- Zhang, Z., Kang, S.M., LeBlanc, A., Hajduk, S.L., Morrow, C.D., 1996. Nucleotide sequences within the U5 region of the viral RNA genome are the major determinants for a human immunodeficiency virus type 1 to maintain a primer binding site complementary to tRNA<sup>His</sup>. Virology 226, 306–317.
- Zhang, Z., Kang, S.-M., Li, Y., Morrow, C.D., 1998. Genetic analysis of the U5-PBS of a novel HIV-1 reveals multiple interactions between the tRNA and RNA genome required for initiation of reverse transcription. RNA 4, 394–406.